Expression of thevavOncogene in Somatic Cell Hybrids

doi:10.1006/excr.1997.3535

Experimental Cell Research

Volume 232, Issue 2, 1 May 1997, Pages 388-394

https://doi.org/10.1006/excr.1997.3535 Get rights and content

Abstract

Thevavoncogene is expressed primarily in tissues of hematopoietic origin. While much effort has been focused on determining the role ofvavin various signal transduction pathways, little is known about the mechanism by whichvavis regulated in a tissue-selective manner. This issue was examined by developing somatic cell hybrids between human U937 cells, which expressvav,and mouse Balb/c 3T3 cells, which do not. Ifvavis primarily regulated by the presence of positive acting transcription factors, thenvavexpression should be maintained in hybrid cells. In contrast, if the regulation ofvavis primarily negative in nature, thenvavexpression should be extinguished in most of the somatic cell hybrids. Of the hybrid cells that were obtained, 64% were positive by reverse transcriptase–polymerase chain reaction for the expression of thevavoncogene. Differences in the pattern of restriction enzyme cleavage sites between the mouse and human PCR products were used to determine that 6 of 11 of the positive clones expressed the normally dormant mouse gene. The other positive clones were found to express the humanvavgene. In all cases, the hybrid cells preferentially retained the chromosomes and the cellular morphological appearance of the mouse Balb/c 3T3 fusion partner, which does not express thevavoncogene. Sincevavis able to be transiently expressed by hybrid cells with a predominately mouse phenotype, these results support the hypothesis thatvavis regulated primarily by the presence of transactivating factors which stimulate transcription, rather than by a gene silencing mechanism.

References (50)

A.F.G. Quest et al.
J. Biol. Chem.
(1992)
C.V. Clevenger et al.
J. Biol. Chem.
(1995)
M. van Lohuizen et al.
Cell
(1991)
M. Alai et al.
J. Biol. Chem.
(1992)
S. Uddin et al.
J. Biol. Chem.
(1995)
C.V. Clevenger et al.
J. Biol. Chem.
(1995)
L.C. Platanias et al.
J. Biol. Chem.
(1994)
P. Chomczynski et al.
Anal. Biochem.
(1987)
M.H. Baron
Curr. Opin. Cell. Biol.
(1993)
M.H. Baron et al.
Cell
(1986)

E.C. Hardeman et al.

Cell

(1986)

M.J. Thayer et al.

Cell

(1990)

S. Katzav et al.

EMBO J.

(1989)

S. Katzav et al.

Mol. Cell. Biol.

(1991)

J. Coppola et al.

Cell Growth Differ.

(1991)

J.M. Adams et al.

Oncogene

(1992)

F. Galland et al.

Oncogene

(1992)

M.S. Boguski et al.

Nature

(1992)

E. Gulbins et al.

Mol. Cell. Biol.

(1994)

S. Katzav et al.

Oncogene

(1995)

R. Khosravi-Far et al.

Mol. Cell. Biol.

(1994)

X.R. Bustelo et al.

Oncogene

(1994)

O. Hobert et al.

Mol. Cell. Biol.

(1996)

F. Romero et al.

Mol. Cell. Biol.

(1996)

Cited by (5)

Defective Vav expression and impaired F-actin reorganization in a subset of patients with common variable immunodeficiency characterized by T-cell defects
2005, Blood
Citation Excerpt :
It has been proposed that the regulation of Vav expression is achieved by stage- and tissue-specific transcriptional activators rather than by epigenetic modifications of the gene promoter.60 This notion is supported by the finding that VAV1 expression can be reactivated in mouse 3T3 fibroblasts by fusion with human monocytic U937 cells, which express Vav.61 Analysis of the VAV1 gene promoter has identified a 23-bp segment essential for tissue-specific regulation, which includes a 7-bp potential core binding factor/acute myeloid leukemia 1 (CBF/AML-1) binding site.42
Common variable immunodeficiency (CVID) is a primary immune disorder characterized by impaired antibody production, which is in many instances secondary to defective T-cell function (T-CVID). We have previously identified a subset of patients with T-CVID characterized by defective T-cell receptor (TCR)-dependent protein tyrosine phosphorylation. In these patients, ZAP-70 fails to be recruited to the TCR as the result of impaired CD3ζ phosphorylation, which is, however, not dependent on defective Lck expression or activity. Here we show that neither Fyn nor CD45 is affected in these patients. On the other hand, T-CVID T cells show dramatic defects in the Vav/Rac pathway controlling F-actin dynamics. A significant deficiency in Vav protein was indeed observed; in 3 of 4 patients with T-CVID, it was associated with reduced VAV1 mRNA levels. The impairment in Vav expression correlated with defective F-actin reorganization in response to TCR/CD28 coengagement. Furthermore, TCR/CD28-dependent up-regulation of lipid rafts at the cell surface, which requires F-actin dynamics, was impaired in these patients. The actin cytoskeleton defect could be reversed by reconstitution of Vav1 expression in the patients' T cells. Results demonstrate an essential role of Vav in human T cells and strongly suggest Vav insufficiency in T-CVID. (Blood. 2005;106:626-634)
Regulation of the vav proto-oncogene by LKLF
2001, Gene
The transcriptional induction of the vav proto-oncogene coincides with the first appearance of the definitive hematopoietic stem cell in the aorta-gonad-mesonephros region. Vav promoter activity was dependent on a previously identified 23 bp DNA segment containing PU.1 and Runx1/AML-1 binding sites and on a newly identified, highly conserved, 12 bp DNA segment (Box B). The sequence of Box B was identical in the human, mouse and rat species. Mutation of the CACCC core sequence led to diminished vav promoter activity. A protein complex which bound to Box B was found in hematopoietic cells but not in cells which did not express vav. A double-stranded oligonucleotide containing a mutation of the CACCC core was less effective in electro-mobility shift assay competitions than the wild-type sequence. UV crosslinking studies identified a 37 kDa DNA binding protein which interacted with Box B in U937 cells. Antibody supershift assays identified this protein as lung Krüppel-like factor (LKLF). LKLF, expressed as a glutathione S-transferase fusion protein, was capable of binding to Box B. A dominant-negative LKLF was able to inhibit the expression of enhanced green fluorescent protein by the vav promoter and chromatin immunoprecipitations detected LKLF bound to the vav promoter in U937 but not HeLa cells. These in vitro results suggest future in vivo experiments to examine the role of LKLF, a gene required for vasculogenesis, in the induction of vav during the genesis of the definitive hematopoietic stem cell from the vascular endothelium.
Genomic organization and regulation of the vav proto-oncogene
2000, Biochimica et Biophysica Acta-Gene Structure and Expression
Vav and vav2 are members of the dbl family of guanine nucleotide exchange factors (GEF) for the rho/rac family of GTP binding proteins. Vav is expressed primarily in hematopoietic cells, while vav2 has a wider tissue distribution. The genomic structure of the human vav proto-oncogene was studied by identifying and sequencing all 27 exons of the gene from overlapping P1 and cosmid clones. The gene spans a 77-kb region on chromosome 19. In contrast, the coding region of vav2 is distributed over 30 exons spanning 227-kb. The overall organization of the exons which encode both proteins was found to be similar. In humans, alternative splicing of exons 6, 16 and 28 generated at least two distinct vav2 mRNA species. Several differences from the original vav cDNA sequence were noted. The most important difference was the identification of amino acid 718 as isoleucine, rather than threonine. This change warrants the reclassification of the vav SH2 domain as a type 3 SH2, instead of a type 2 SH2 as originally proposed by Songyang et al. (Mol. Cell. Biol. 14 (1994) 2777–2785). A series of vav promoter deletions were constructed using the enhanced green fluorescent protein (EGFP) as a reporter gene. A 23-bp segment that included a potential CBF/AML-1 binding site was found to be essential for EGFP expression in U937 cells. The same constructs were not active in HeLa cells, which do not express vav. A potential c-myb DNA binding site within the vav promoter was not required for EGFP expression.
Human Vav1 expression in hematopoietic and cancer cell lines is regulated by c-Myb and by CpG methylation
2012, PLoS ONE
PU.1 regulates the expression of the Vav proto-oncogene
2002, Journal of Cellular Biochemistry

¹: To whom correspondence and reprint requests should be addressed. Fax: (402) 559-7495.

View full text

Regular ArticleExpression of thevavOncogene in Somatic Cell Hybrids

Abstract

J. Biol. Chem.

J. Biol. Chem.

Cell

J. Biol. Chem.

J. Biol. Chem.

J. Biol. Chem.

J. Biol. Chem.

Anal. Biochem.

Curr. Opin. Cell. Biol.

Cell

Cell

Cell

EMBO J.

Mol. Cell. Biol.

Cell Growth Differ.

Oncogene

Oncogene

Nature

Mol. Cell. Biol.

Oncogene

Mol. Cell. Biol.

Oncogene

Mol. Cell. Biol.

Mol. Cell. Biol.

Regular Article
Expression of thevavOncogene in Somatic Cell Hybrids